Charles Schwab Investment Management Inc Iveric Bio, Inc. Transaction History

Charles Schwab Investment Management Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$26.24 - $39.63 $435,137 - $657,184	16,583 Added 1.7%	994,037 $39.1 Million
Q1 2023 May 11, 2023	BUY	$18.67 - $24.56 $244,446 - $321,564	13,093 Added 1.36%	977,454 $23.8 Million
Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $2.42 Million - $3.36 Million	140,208 Added 17.01%	964,361 $20.6 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $4.91 Million - $9.71 Million	522,265 Added 173.0%	824,153 $14.8 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $6,128 - $12,700	672 Added 0.22%	301,888 $2.91 Million

Q1 2022 May 13, 2022	BUY	$12.15 - $16.83 $76,374 - $105,793	6,286 Added 2.13%	301,216 $5.07 Million
Q4 2021 Feb 11, 2022	BUY	$13.83 - $18.78 $431,399 - $585,804	31,193 Added 11.83%	294,930 $4.93 Million
Q3 2021 Nov 16, 2021	BUY	$7.07 - $17.5 $263,894 - $653,205	37,326 Added 16.49%	263,737 $4.28 Million
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $114,397 - $144,152	20,105 Added 9.75%	226,411 $1.43 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $26,095 - $35,393	5,137 Added 2.55%	206,306 $1.28 Million
Q4 2020 Feb 16, 2021	SELL	$5.65 - $7.66 $361 - $490	-64 Reduced 0.03%	201,169 $1.39 Million
Q3 2020 Nov 13, 2020	BUY	$4.01 - $6.29 $379,446 - $595,191	94,625 Added 88.76%	201,233 $1.14 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $326,220 - $703,612	106,608 New	106,608 $544,000
Q3 2019 Nov 08, 2019	SELL	$1.09 - $1.29 $32,003 - $37,875	-29,361 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$1.21 - $1.48 $35,526 - $43,454	29,361 New	29,361 $39,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.